A. Pranzo
Astellas Pharma (United Kingdom)(GB)
Publications by Year
Research Areas
Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Liver Disease Diagnosis and Treatment, Cancer, Lipids, and Metabolism, Prostate Cancer Diagnosis and Treatment
Most-Cited Works
- → A European, prospective, observational study of enzalutamide in patients with metastatic castration‐resistant prostate cancer: PREMISE(2021)19 cited
- → Incidencia, prevalencia y patrones de tratamiento del cáncer de próstata metastásico hormonosensible en España: Estudio ECHOS(2022)5 cited
- → Enzalutamide versus abiraterone acetate in the development of new-onset or worsening type 2 diabetes mellitus in patients with metastatic castration-resistant prostate cancer: EVADE study(2024)5 cited
- → Incidence, prevalence, and treatment patterns in metastatic hormone-sensitive prostate cancer in Spain: ECHOS study(2022)2 cited
- [Determination of cholylglycine in alcoholic hepatopathies. Clinical usefulness].(1985)
- → New or worsening type 2 diabetes mellitus (T2DM) in men treated with enzalutamide (ENZ) or abiraterone acetate (AA) for metastatic castration-resistant prostate cancer (mCRPC): EVADE study(2023)1 cited
- [Determination of serum bile acids in hepatobiliary diseases. Clinical applicability].(1984)
- → Attributes and Health Care Resource Utilization of Patients on Enzalutamide or Abiraterone for Metastatic Castration-Resistant Cancer in England(2025)1 cited
- → A European prospective observational study of enzalutamide (ENZA) in patients with metastatic castration-resistant prostate cancer (mCRPC): PREMISE(2020)1 cited
- → Treatment intensification in metastatic castration-sensitive prostate cancer: a real-world study in Alberta, Canada(2025)1 cited